GlassScriptPhysician profile
Corinna Ann Brander
NPI 1881139434
$9,054.67
in general payments reported to CMS, 2019-2025
20 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $2,541 · 2023: $1,254 · 2024: $3,610 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171 · Consulting Fee: $1,350 · Education: $601 · Travel and Lodging: $366 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.85 |
| Consulting Fee | $1,350.00 |
| Education | $600.99 |
| Travel and Lodging | $365.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $2,344.69 | 2023-2025 | |
| Banner Life Sciences, LLC | $1,762.04 | 2021-2022 | |
| Biogen, INC. | $1,375.61 | 2021-2025 | Vumerity, Tysabri, Tecfidera |
| Alexion Pharmaceuticals, INC. | $691.24 | 2021-2024 | Ultomiris, Soliris |
| Genentech USA, INC. | $662.53 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $640.88 | 2021-2023 | |
| Emd Serono, INC. | $447.54 | 2023-2025 | Mavenclad |
| Abbvie INC. | $257.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $244.30 | 2022-2024 | |
| Eisai INC. | $216.29 | 2023-2025 | |
| Lundbeck LLC | $143.15 | 2023-2024 | Vyepti |
| Pfizer INC. | $108.97 | 2023-2025 | |
| Amgen INC. | $30.47 | 2025 | Uplizna |
| Celgene Corporation | $29.33 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.95 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.83 | 2021 | |
| Livanova USA, INC. | $15.67 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Irhythm Technologies, INC. | $15.52 | 2023 | Zio Xt Patch |
| Teva Pharmaceuticals USA, INC. | $14.71 | 2025 | Austedo Xr |
| Sk Life Science, INC. | $14.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinna Brander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.